Mandate

Vinge advises Industrifonden in connection with investment in Smartfish

September 18, 2013

Industrifonden is investing SEK 35 million in the Norwegian company, Smartfish, which develops Omega 3 drinks within the field of clinical nutrition. The current owner, Investinor and private investors are also participating in the new issue valued at approximately SEK 80 million. The money will primarily be used for clinical trials and future international expansion. Smartfish develops prescription-based Omega 3-enriched drinks in the form of fruit juice for, e.g. cancer patients, who often develop cachexia, i.e. emaciation caused by significant, long-term malnourishment. At the same time, a new product for Alzheimer patients is being developed. The company holds a patented method which makes it possible to introduce high doses of Omega 3 fatty acid into the juice without affecting its taste.

Smartfish is headquartered in Oslo, although production occurs in Sweden. The company has recently been awarded a procurement contract pertaining to clinical nutrition in Skåne, which will be launched in Sweden this autumn. As a result of the capital infusion, an R&D centre will be established in Stockholm.

The investment in Starfish is the first stage of a recently commenced life science co-operation between Industrifonden and the Norwegian investment enterprise, Investinor. The aim is to give attractive life science companies access to international capital.

Vinge’s team consisted of partner Johan Larsson and associate Alexandra Kempe.   

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025